Crossref
FDA Approves a Second Weekly Basal Insulin Option for Type 2 Diabetes
JAMA · 10.11.2026 · 336 (18) · 1594
DOI: 10.1001/jama.2026.20020 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 10.11.2026. Verfasst von Samantha Anderer.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Anderer, S. (2026). FDA Approves a Second Weekly Basal Insulin Option for Type 2 Diabetes. JAMA, 336(18), 1594. https://doi.org/10.1001/jama.2026.20020
Vancouver
Anderer S. FDA Approves a Second Weekly Basal Insulin Option for Type 2 Diabetes. JAMA. 2026;336(18):1594. doi:10.1001/jama.2026.20020
BibTeX
@article{Anderer2026,
author = {Anderer, Samantha},
title = {FDA Approves a Second Weekly Basal Insulin Option for Type 2 Diabetes},
journal = {JAMA},
year = {2026},
volume = {336},
number = {18},
pages = {1594},
doi = {10.1001/jama.2026.20020}
}
EUVIMED